# Market Surge: Oil Dreams and Stock Schemes! Newsy: Bud Fox's 3 Controversial Stocks of the Day Published: 2026-03-17T14:01:22.785Z Source: https://newsyai.com/edition/34b8e11f-8815-46d3-85e0-107cf508d804 Archive: https://newsyai.com/newsy/bde0e0f6-7fac-4abb-93a8-996b5464e3e9.md --- # Futures Flex Muscles, Iran Oil Boner at $102: Acqui-Hype Orgasms & FDA Fisting Frenzy! **Premarket popping like Viagra Viagra**—**Dow futures +0.94% ~47,030**[[web:121]](https://www.benzinga.com/premarket), **S&P +0.78% ~6,690**, **Nasdaq +0.87% ~24,900** as Brent oil **eyes $102** on PGIM's Iran "Hydra Holdout" wet dream (prolonged proxy prick-fest?).[[1]](https://www.benzinga.com/premarket) Microcaps mooning harder than a full eclipse: ATXG lending lust, ALDX eye-drop enema, LIDR lidar load. Three ball-busting battles: bulls blue-balled, bears bitch-slapped, my no-bullshit breakdown.[[1]](https://www.benzinga.com/premarket) --- ## 1) Addentax Group (ATXG): “Fintech Flip-Off Flip” vs “Dilution Dong-Swing Disaster” **Why it’s loud** **ATXG** blasting **+71.53% pre to ~$0.44** on fresh announcement of **negotiations to acquire multiple leading online money-lending platforms**—diving into AI/crypto lending cesspool amid China fintech famine.[[1]](https://www.benzinga.com/premarket)[[2]](https://www.benzinga.com/m-a/26/03/51295787/addentax-group-announces-negotiations-to-acquire-multiple-leading-online-money-lending-platforms-acr) **Bull case (lending loadout legend)** Bolt-on rev rocket: HK$2B+ loan volume platforms = annualized cash cow, Middle East royal $200M infusion vibes; AI edge in high-yield loans crushes legacy banks.[[2]](https://www.benzinga.com/m-a/26/03/51295787/addentax-group-announces-negotiations-to-acquire-multiple-leading-online-money-lending-platforms-acr)[[3]](https://www.prnewswire.com/news-releases/addentax-group-corp-entered-into-memorandum-of-understanding-for-potential-us200-million-strategic-investment-with-middle-east-royal-backed-institutional-investors-at-proposed-price-of-1-50-per-share-supporting-ai-and-crypto-s-302683753.html) **Bear case (acqui-fart flop)** Serial acqui-whiffer: Past Keemo $5.5M buy dilution diarrhea, microcap merger meatgrinder—execution erectile dysfunction if regs rimjob or integration implodes.[[4]](https://www.stocktitan.net/sec-filings/ATXG/8-k-a-addentax-group-corp-amends-material-event-report-294e5e0e6c5a.html) **My take, first principles (China credit crunch cream vs penny pump-puke)** Core the collateral: $1T+ P2P lending TAM in Asia, ATXG's logistics pivot to fintech = sticky borrower moat—but Nasdaq turd history screams dilution dump. Hype hump: **Buy $0.38-0.42**, **$0.60/$0.75 calls** deal dong—**puts $0.30** bust. Risk: Negotiation nut-tap.[[2]](https://www.benzinga.com/m-a/26/03/51295787/addentax-group-announces-negotiations-to-acquire-multiple-leading-online-money-lending-platforms-acr) --- ## 2) Aldeyra Therapeutics (ALDX): “Pipeline Pivot Prick” vs “FDA Rejection Rimjob” **Why it’s loud** **ALDX** cratering **-72.82% pre to ~$1.15** after **FDA slaps Complete Response Letter on reproxalap dry-eye NDA**—third strike? Eyeball enema dreams deferred again.[[1]](https://www.benzinga.com/premarket)[[5]](https://www.investing.com/news/company-news/fda-rejects-aldeyras-dry-eye-disease-drug-application-93CH-4565779) **Bull case (rebound rocket ride)** Cash runway +$100M, pipeline pricks like ADX-629 asthma/nasal polyposis = Phase 3 spunk; past CRLs led to surges—buy the FDA faceplant.[[6]](https://www.gurufocus.com/news/8719135/aldeyra-aldx-faces-fda-setback-on-dry-eye-disease-drug-application) **Bear case (serial rejection shitshow)** Reproxalap rejected *again* (PDUFA March 16), history of FDA fisting—pivot costs cash burn, dilution dong looms in $10B dry-eye dogfight.[[5]](https://www.investing.com/news/company-news/fda-rejects-aldeyras-dry-eye-disease-drug-application-93CH-4565779)[[7]](https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-approve-aldeyras-eye-disease-drug-2025-04-03) **My take, first principles (ocular inflammation oasis vs biotech black hole)** Peel the pupil: $5B+ dry-eye TAM desperate for non-steroid salvation, but ALDX's RASP modulator misses = data dud. Bloodbath bottom: **Dip $0.95-1.05**, **$1.50/$2 calls** appeal ass-kiss—**puts $0.80** death spiral. Risk: NDA necro.[[5]](https://www.investing.com/news/company-news/fda-rejects-aldeyras-dry-eye-disease-drug-application-93CH-4565779) --- ## 3) AEye (LIDR): “Lidar Laser Load” vs “Cash-Burn Corpse” **Why it’s loud** **LIDR** ripping **+47.09% pre to ~$2.28** post-Q4 earnings dump (March 16 after close)—lidar for AVs beaming amid Nvidia GTC buzz, 200-DMA breakout tease.[[1]](https://www.benzinga.com/premarket)[[8]](https://www.stocktitan.net/news/LIDR) **Bull case (AV apocalypse accelerator)** Earnings beat vibes + Nvidia tie-up whispers = $50B lidar TAM thrust, 36% YTD pop; Strong Buy $6 PT = 160% bag.[[9]](https://stocktwits.com/news-articles/markets/equity/lidr-stock-rising-today-nvidia-deal-200dma-breakout/cZ3Ec3jRIQu)[[10]](https://www.msn.com/en-us/money/stockdetails/lidr-us-stock/fi-bxb5jc) **Bear case (fabless flop fantasy)** Chronic bleeder, AV winter + Waymo/Luminar crush—earnings vapor if guidance gags, dilution deluge.[[11]](https://www.ainvest.com/news/lidr-surges-38-breakout-real-2603) **My take, first principles (adaptive lidar lock vs robotaxi roadkill)** Strip the sensor: Level 4 AV needs 4D perception punch, LIDR's aero-spec = edge in drones/defense (Iran boost?)—but capex corpse. Earnings erection: **Dip $2.00-2.10**, **$3/$4 calls** GTC gush—**puts $1.80** fade. Risk: Guidance girth.[[8]](https://www.stocktitan.net/news/LIDR) --- ## Tape-Side Tactics (chamber the round or chug the load) - **ATXG**: **$0.38-0.42** acqui ass-grab; **$0.60C/$0.75C** spreads, **P$0.30** deal dump.[[2]](https://www.benzinga.com/m-a/26/03/51295787/addentax-group-announces-negotiations-to-acquire-multiple-leading-online-money-lending-platforms-acr) - **ALDX**: **$0.95-1.05** FDA flush; **$1.50C/$2C**, **P$0.80** biotech bitch.[[5]](https://www.investing.com/news/company-news/fda-rejects-aldeyras-dry-eye-disease-drug-application-93CH-4565779) - **LIDR**: **$2.00-2.10** lidar lift; **$3C/$4C**, **P$1.80** earnings enema.[[8]](https://www.stocktitan.net/news/LIDR) Iran oil orgasm or de-escalation deflation? Micro mayhem or macro mutilation? DYOR, thrust or bust.